Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTUYPMZJ)

DOT Name Butyrophilin subfamily 2 member A1 (BTN2A1)
Gene Name BTN2A1
Related Disease
Breast carcinoma ( )
Gastroesophageal reflux disease ( )
High blood pressure ( )
Major depressive disorder ( )
rubella ( )
Schizophrenia ( )
Chronic kidney disease ( )
Coronary atherosclerosis ( )
Coronary heart disease ( )
Lung carcinoma ( )
Myocardial infarction ( )
Non-insulin dependent diabetes ( )
Systemic lupus erythematosus ( )
Type-1/2 diabetes ( )
UniProt ID
BT2A1_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
8DFW; 8DFX; 8DFY; 8JYC; 8JYE
Pfam ID
PF13765 ; PF00622 ; PF07686
Sequence
MESAAALHFSRPASLLLLLLSLCALVSAQFIVVGPTDPILATVGENTTLRCHLSPEKNAE
DMEVRWFRSQFSPAVFVYKGGRERTEEQMEEYRGRTTFVSKDISRGSVALVIHNITAQEN
GTYRCYFQEGRSYDEAILHLVVAGLGSKPLISMRGHEDGGIRLECISRGWYPKPLTVWRD
PYGGVAPALKEVSMPDADGLFMVTTAVIIRDKSVRNMSCSINNTLLGQKKESVIFIPESF
MPSVSPCAVALPIIVVILMIPIAVCIYWINKLQKEKKILSGEKEFERETREIALKELEKE
RVQKEEELQVKEKLQEELRWRRTFLHAVDVVLDPDTAHPDLFLSEDRRSVRRCPFRHLGE
SVPDNPERFDSQPCVLGRESFASGKHYWEVEVENVIEWTVGVCRDSVERKGEVLLIPQNG
FWTLEMHKGQYRAVSSPDRILPLKESLCRVGVFLDYEAGDVSFYNMRDRSHIYTCPRSAF
SVPVRPFFRLGCEDSPIFICPALTGANGVTVPEEGLTLHRVGTHQSL
Tissue Specificity Highly expressed in brain, bone marrow, small intestine, muscle, spleen and pancreas. Moderate expression was seen in lung, liver and kidney.
Reactome Pathway
Butyrophilin (BTN) family interactions (R-HSA-8851680 )

Molecular Interaction Atlas (MIA) of This DOT

14 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Breast carcinoma DIS2UE88 Strong Genetic Variation [1]
Gastroesophageal reflux disease DISQ8G5S Strong Genetic Variation [2]
High blood pressure DISY2OHH Strong Biomarker [3]
Major depressive disorder DIS4CL3X Strong Genetic Variation [4]
rubella DISXUI9P Strong Biomarker [5]
Schizophrenia DISSRV2N Strong Genetic Variation [6]
Chronic kidney disease DISW82R7 moderate Biomarker [7]
Coronary atherosclerosis DISKNDYU Limited Genetic Variation [8]
Coronary heart disease DIS5OIP1 Limited Genetic Variation [8]
Lung carcinoma DISTR26C Limited Genetic Variation [9]
Myocardial infarction DIS655KI Limited Genetic Variation [8]
Non-insulin dependent diabetes DISK1O5Z Limited Biomarker [10]
Systemic lupus erythematosus DISI1SZ7 Limited Genetic Variation [11]
Type-1/2 diabetes DISIUHAP Limited Genetic Variation [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 Disease(s)
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
7 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate decreases the expression of Butyrophilin subfamily 2 member A1 (BTN2A1). [12]
Ciclosporin DMAZJFX Approved Ciclosporin increases the expression of Butyrophilin subfamily 2 member A1 (BTN2A1). [13]
Tretinoin DM49DUI Approved Tretinoin increases the expression of Butyrophilin subfamily 2 member A1 (BTN2A1). [14]
Liothyronine DM6IR3P Approved Liothyronine decreases the expression of Butyrophilin subfamily 2 member A1 (BTN2A1). [15]
Urethane DM7NSI0 Phase 4 Urethane increases the expression of Butyrophilin subfamily 2 member A1 (BTN2A1). [16]
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene increases the expression of Butyrophilin subfamily 2 member A1 (BTN2A1). [17]
Formaldehyde DM7Q6M0 Investigative Formaldehyde increases the expression of Butyrophilin subfamily 2 member A1 (BTN2A1). [18]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Drug(s)

References

1 Association analysis identifies 65 new breast cancer risk loci.Nature. 2017 Nov 2;551(7678):92-94. doi: 10.1038/nature24284. Epub 2017 Oct 23.
2 Gastroesophageal reflux GWAS identifies risk loci that also associate with subsequent severe esophageal diseases.Nat Commun. 2019 Sep 16;10(1):4219. doi: 10.1038/s41467-019-11968-2.
3 Association of genetic variants with hypertension in a longitudinal population-based genetic epidemiological study.Int J Mol Med. 2015 May;35(5):1189-98. doi: 10.3892/ijmm.2015.2151. Epub 2015 Mar 20.
4 Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways.Nat Genet. 2018 Jul;50(7):920-927. doi: 10.1038/s41588-018-0151-7. Epub 2018 Jun 25.
5 Genetic polymorphisms associated with rubella virus-specific cellular immunity following MMR vaccination.Hum Genet. 2014 Nov;133(11):1407-17. doi: 10.1007/s00439-014-1471-z. Epub 2014 Aug 7.
6 Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia.Mol Autism. 2017 May 22;8:21. doi: 10.1186/s13229-017-0137-9. eCollection 2017.
7 Association of genetic variants with dyslipidemia and chronic kidney disease in a longitudinal population-based genetic epidemiological study.Int J Mol Med. 2015 May;35(5):1290-300. doi: 10.3892/ijmm.2015.2152. Epub 2015 Mar 20.
8 Association of a polymorphism of BTN2A1 with dyslipidemia in community-dwelling individuals.Mol Med Rep. 2014 Mar;9(3):808-12. doi: 10.3892/mmr.2014.1902. Epub 2014 Jan 16.
9 Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes.Nat Genet. 2017 Jul;49(7):1126-1132. doi: 10.1038/ng.3892. Epub 2017 Jun 12.
10 Association of a polymorphism of BTN2A1 with type 2 diabetes mellitus in Japanese individuals.Diabet Med. 2011 Nov;28(11):1381-7. doi: 10.1111/j.1464-5491.2011.03358.x.
11 GWAS identifies novel SLE susceptibility genes and explains the association of the HLA region.Genes Immun. 2014 Sep;15(6):347-54. doi: 10.1038/gene.2014.23. Epub 2014 May 29.
12 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
13 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
14 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
15 Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
16 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
17 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
18 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.